Skip to main content

Table 3 Comparison serum profiles short PFS vs. long PFS

From: Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling

m/z

p-value

2489.3052

0.018082

2318.2202

0.030239

2209.0934

0.041789**

2215.2849

0.041789

2376.2096

0.041789

1545.616

0.048844

  1. Six peaks were significantly differential comparing NSCLC patients with short progression-free survival and long progression-free survival. All peaks were up-regulated in the group with short progression-free survival. None of the six peaks were positively identified. Ordered by p-value. ** identified by Tempst et al. as high-molecular-weight kininogen [19].